Corbus Pharmaceuticals Holdings Inc CRBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRBP is a good fit for your portfolio.
News
-
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
-
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
-
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Corbus Pharmaceuticals Announces Pricing of Public Offering
-
Corbus Pharmaceuticals Announces Proposed Public Offering
Trading Information
- Previous Close Price
- $39.24
- Day Range
- $36.82–39.94
- 52-Week Range
- $3.03–49.87
- Bid/Ask
- $33.00 / $39.10
- Market Cap
- $396.12 Mil
- Volume/Avg
- 94,730 / 301,359
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.corbuspharma.com
Valuation
|
Metric
|
CRBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRBP
|
|---|---|
Quick Ratio | 0.66 |
Current Ratio | 0.74 |
Interest Coverage | −14.25 |
Quick Ratio
CRBP
Profitability
|
Metric
|
CRBP
|
|---|---|
Return on Assets (Normalized) | −90.95% |
Return on Equity (Normalized) | −392.87% |
Return on Invested Capital (Normalized) | −112.60% |
Return on Assets
CRBP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pngjpsth | Fvdlw | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dgdbdnzm | Syxdrms | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yvqbqzgj | Dcgrfkc | $98.8 Bil | |
MRNA
| Moderna Inc | Nzclrxwb | Jgtr | $38.8 Bil | |
ARGX
| argenx SE ADR | Frqwgqrtj | Cmc | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Kbhyqknm | Cvmz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykpshvgt | Sdwkld | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dtpvqyqz | Bssyjf | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xdsbrdmsqs | Tlmktm | $12.4 Bil | |
INCY
| Incyte Corp | Ncdzqkx | Pbvyv | $11.9 Bil |